As filed with the Securities and Exchange Commission on August 7, 2002



                                    FORM 6-K

                       SECURITIES AND EXCHANGE COMMISSION


                             Washington, D.C. 20549

                        Report of Foreign Private Issuer
                      Pursuant to Rule 13a-16 or 15d-16 of
                       the Securities Exchange Act of 1934

                      Results for the month of August 2002


                                  Crucell N.V.
             (Exact name of Registrant as Specified in its Charter)
                                  Crucell N.V.
                 (Translation of Registrant's Name into English)
                                 The Netherlands
                 (Jurisdiction of Incorporation or Organization)
                Archimedesweg 4, 2333 CN Leiden, The Netherlands
                    (Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F

         Form 20-F  [X]                                Form 40-F  [ ]


Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934

         Yes  [ ]                                      No  [X]


If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
                  N/A

<PAGE>
                                  Crucell logo

            Crucell and NIH Extend Ebola Vaccine Agreement to include
                           Marburg and Lassa Vaccines

Leiden, The Netherlands, August 7, 2002 - Dutch antibody and vaccine company
Crucell N.V. (Euronext, NASDAQ: CRXL) today announced that it has expanded the
Research Plan of its Cooperative Research and Development Agreement with the
Vaccine Research Center of the National Institute of Allergy and Infectious
Diseases (NIAID). The NIAID is part of the United States of America's primary
biomedical research institute, the National Institutes of Health (NIH). In May
2002, Crucell entered into an agreement with the NIAID to develop an Ebola
vaccine. The Research Plan of this agreement has now been expanded to include
the development of vaccines to protect against Marburg and Lassa infections.

The vaccines against these diseases will be based on Crucell's vaccination
platform, AdVac(TM), and produced on Crucell's human cell line, PER.C6(TM). The
NIAID will create modified Ebola, Marburg and Lassa genes, which will be used in
making the vaccines.

Under the terms of the agreement, Crucell has the option for exclusive
commercialization rights to the Ebola, Marburg and Lassa vaccines. The vaccines
are targeted towards people living in disease endemic areas in Africa,
travelers, government officials, and military personnel. The vaccines could be
useful for biodefense against the deliberate release of these agents if they
were to be used for biological warfare.

"There is a great need globally for vaccines against hemorrhagic fevers. Crucell
believes that our Advac(TM) platform technology can make such vaccines a
reality," said Dr. Jaap Goudsmit, Chief Medical Officer at Crucell.

Ebola and Marburg viruses are related viruses that both cause a highly lethal
syndrome of fever and bleeding, called hemorrhagic fever. Outbreaks of Ebola
fever and Marburg disease have occurred in Africa in recent years, resulting in
hundreds of deaths. Lassa virus is in a different family of viruses. It infects
approximately 100,000-300,000 people a year, causing Lassa fever and resulting
in thousands of deaths. It is endemic in West Africa and is difficult to control
due to the economic, social and political situation in that region. No vaccines
are currently available to prevent or treat humans infected with Ebola, Marburg
or Lassa viruses.

About Crucell

Crucell discovers and develops biopharmaceuticals that use the human immune
system to combat cancer, infectious diseases and other conditions. Crucell
leverages its patented technologies, MAbstractTM, AdVacTM, and PER.C6TM, for
discovery, development and production of antibodies and vaccines. Crucell offers
its technologies to the pharmaceutical and biotechnology industry and also uses
them to create its own product pipeline. Partners include Merck & Co. for the
HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and
Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of
various types of cancer. In addition, Crucell has over 20 licensees for its
PER.C6TM technology. These include Novartis, GSK, Aventis and Schering AG. With
headquarters in Leiden, The Netherlands, the company currently employs 200
people. Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL). For more
information visit www.crucell.com.

For further information please contact:

Crucell N.V.                                     Hill & Knowlton Nederland B.V.
Louise Dolfing                                   Arie Bos
Communications Officer                           Tel. +31-(0)20-404 4707
Tel. +31-(0)71-524 8863                          Fax. +31-(0)20-644 9736
Fax. +31-(0)71-524 8935                          abos@hillandknowlton.com
l.dolfing@crucell.com

<PAGE>

                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.



                                         Crucell N.V.




                                         By: /s/ Leonard Kruimer
                                             --------------------------
                                             Chief Financial Officer


Date: August 7, 2002